We hope that further investigation of the immune response to cancer through use of our autoantibody platform will lead to a greater understanding of this highly complex area of science so that early detection tests for all cancers can be achieved
De Soto, KS (PRWEB) May 11, 2011
Oncimmune announces that the autoantibody platform used in their proprietary EarlyCDT-Lung test is being made available for independent research at the Centre for Excellence for Autoimmunity in Cancer (CEAC) at the University of Nottingham in the United Kingdom. The research will further assess the performance of EarlyCDT-Lung, a test designed to identify the existence of cancer antigens in patients displaying the earliest symptoms of lung cancer.
Developed by researchers from Oncimmune, the EarlyCDT-Lung test is the first of its kind. This test is designed to aid in the risk assessment and early detection of lung cancer. Currently, in most cases, a diagnosis is made only after the disease has progressed and the patient begins displaying symptoms of lung cancer. The EarlyCDT-Lung test is a blood test which analyzes a multi–antigen panel to detect autoantibodies that have been associated with lung cancer antigens. Autoantibodies are produced in the very early stages of lung cancer, potentially enabling doctors to detect the disease before it has time to progress.
“Early diagnosis of lung cancer before it has spread and therefore while curable remains the goal for screening tests. The EarlyCDT-Lung test is a new technology with the potential to shift our ability to diagnose lung cancer earlier than is currently achieved,” said Dr. James Jett of National Jewish Health. “Preliminary data, auditing the use of the test in clinical practice, are promising and consistent with the case-controlled studies. I am hopeful that the studies planned by CEAC will validate the test’s clinical performance in a screening context and its cost effectiveness.”
The world’s first Centre for Excellence for Autoimmunity in Cancer (CEAC) was recently established at the Nottingham University. The CEAC houses a multi-disciplinary team working to discover new insights into the biological makeup of cancer and encourage further studies in order to develop a fundamental understanding of the disease. CEAC has been granted access to Oncimmune’s EarlyCDT-Lung technology to allow academic research into the immune system’s response to cancer.
“Finding lung cancer at the earliest stage possible, even before lung cancer symptoms are evident, does increase survival rates and the likelihood of a better outcome for the patient.” commented Dan Calvo, President and CEO of Oncimmune. “We hope that further investigation of the immune response to cancer through use of our autoantibody platform will lead to a greater understanding of this highly complex area of science so that early detection tests for all cancers can be achieved."
Oncimmune launched EarlyCDT-Lung in the United States in 2009. Results of the commercial launch will be presented at the World Congress for Lung Cancer in Amsterdam in July. EarlyCDT-Lung is scheduled to launch commercially in the United Kingdom later this year. In addition, Oncimmune plans to launch EarlyCDT-Lung test for other solid tumor cancer in the coming years. Look for more exciting developments from Oncimmune as they take strides to advance early cancer detection through autoantibody assay technology.
Oncimmune (USA) LLC, founded in 2006, is an industry leader in early cancer detection. Oncimmune (USA )LLC is a wholly-owned subsidiary of Oncimmune LTD based in Nottingham, England. The company is committed to advancing early cancer detection through proprietary autoantibody assay technologies based upon biological technology initially identified by John Robertson, M.D., professor of surgery at Nottingham University, England, and Chief Scientific Officer of Oncimmune LTD. Ongoing research and development is conducted by Oncimmune under the direction of Dr. Robertson. The company’s mission is to develop early cancer detection tests to identify more than 90 percent of solid-tumor cancers, which make up 70 percent of all cancers including lung, breast, colorectal, prostate, stomach, pancreatic and ovarian. Oncimmune’s metro Kansas City laboratory is CLIA-certified under the Clinical Laboratory Improvements Amendment of 1988. Oncimmune LTD owns a portfolio of patents including No. 7,402,403 and No. 7,205,117.